TOP TIERMARKET NEWSWIRE

News & sentiment

ONCOLYTICS BIOTECH I (ONCY) — News & AI sentiment

ONCOLYTICS BIOTECH I (ONCY) news roundup. 5 stories in the past week, 9 over 30 days. Average 30-day sentiment is 58.2/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

5

avg sentiment 62/100

30d stories

9

avg sentiment 58.2/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

ONCY news in the last 24 hours, 7 days, 30 days and 90 days

How much ONCY coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ONCY stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	5	62/100	ONCY headlines →
Last 30 days	9	58.2/100	ONCY headlines →
Last 90 days	25	59.1/100	ONCY headlines →

Latest stories on ONCY

Oncolytics Biotech Reports Positive Pelareorep Preclinical Results

TipRanks67 · bullishproduct/pr

3d ago

Oncolytics reports pelareorep preclinical results

The Fly59 · neutralproduct/pr

3d ago

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K50 · neutralgeneral

3d ago

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

Business Insider67 · bullishproduct/pr

3d ago

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

GlobeNewswire67 · bullishproduct/pr

3d ago

Oncolytics price target lowered to $5 from $10 at H.C. Wainwright

The Fly34 · bearishanalyst

Aug 19

Oncolytics aligns with FDA on path for REO 033 expansion study

The Fly63 · neutralproduct/pr

Aug 18

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K50 · neutralgeneral

Aug 18

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

GlobeNewswire67 · bullishproduct/pr

Aug 18

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K34 · bearishgeneral

Jul 24

Oncolytics Biotech gains FDA Fast Track for pelareorep

TipRanks68 · bullishproduct/pr

Jul 20

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K50 · neutralgeneral

Jul 20

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Business Insider67 · bullishproduct/pr

Jul 20

Oncolytics Biotech advances REO 033 colorectal cancer program

TipRanks65 · bullishproduct/pr

Jul 13

Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer

Morningstar63 · neutralproduct/pr

Jul 13

Oncolytics Biotech Advances toward Potential FDA Registration with Expanded Colorectal Cancer Trial July 13, 2026

MarketChameleon73 · bullishproduct/pr

Jul 13

Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)

InvestorsHub67 · bullishgeneral

Jul 13

Why Is Penny Stock Oncolytics Biotech (ONCY) Up Today?

TipRanks56 · neutralgeneral

Jul 13

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K50 · neutralgeneral

Jul 13

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | ONCY Stock News

StockTitan67 · bullishproduct/pr

Jul 13

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K50 · neutralgeneral

Jul 8

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics

Stocktwits News67 · bullishproduct/pr

Jun 16

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

TipRanks63 · neutralproduct/pr

Jun 16

ONCOLYTICS BIOTECH INC (ONCY) files 8-K

SEC 8-K50 · neutralgeneral

Jun 16

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 | ONCY Stock News

StockTitan63 · neutralproduct/pr

Jun 16

Open ONCY in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →